Diagnosis and treatment of anemia in Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Volumn 3, Issue 3, 1997, Pages 204-216

  Schreiber, Stefan ^a   Wedel, Susanne ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anemia; Crohn's disease; Erythropoiesis; Inflammation; Ulcerative colitis; Vitamin B12 deficiency

Indexed keywords

EID: 0002050777     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780030306     Document Type: Review

References (70)

1. Harries AD, Heatly RV. Nutritional disturbances in Crohn's disease. Postgrad Med J 1983;59:690-7.
2. O'Keefe SJD, Rosser BG. Nutrition and inflammatory bowel disease. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:462-83.
3. Surawicz CM. Differential diagnosis of Crohn's disease. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:304, 327, 409, 462.
4. Weatherall DJ. Diseases of the blood. In: Weatherall DJ, Ledingham JGG, Warell DA, eds. Oxford textbook of medicine. Oxford: Oxford University Press, 1984:19.100-19.203.
5. Beck IT. Laboratory assessment in inflammatory bowel disease. Dig Dis Sci 1987; 32;S42-5.
6. Cooke WT, Prior P. Determining disease activity in inflammatory bowel disease. J Clin Gastroenterol 1984;6:17-25.
7. Bubley GJ, Lange RF. Microcytic anemias. In: Robinson SH, Reich PR. Hematology: pathophysiologic basis for clinical practice. Boston: Little Brown, 1993:35-74.
8. Beal RW, Skyring AP, McRae J, et al. The anemia of ulcerative colitis. Gastroenterology 1963;45:589-71.
9. Levine DS. Clinical features and complications of Crohn's disease. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:296-316.
10. Krantz SB. Erythropoetin and the anemia of chronic disease: state of the art lecture. Nephrol Dial Transplant 1995;10:10-7.
11. Paganini EP. In search of an optimal hemocrit level in patients: rehabilitation and quality-of-life implications. Am J Kidney 1994; 24:S10-6.
12. Horina JH, Petrisch W, Schmid CR, Reicht G, Wenzl H, Silly H, Krejs J. Treatment of anemia in inflammatory bowel disease with recombinant erythropoietin: results in three patients. Gastroenterology 1993;104:1828-31.
13. Schreiber S, Howaldt S, Schnoor M, Nicolaus S, Bauditz J, Gasche C, Lochs H, Raedler A. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996;334:619-23.
14. Gasche C, Reinisch W, Lochs H, Parsaei B, Bakos S, Wyatt J, Fueger GF, Gangl A. Anemia in Crohn's disease: importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 1994;39:1930-4.
15. Metcalf D. The molecular control of cell division: differentiation commitment and maturation in hematopoetic cells. Nature 1989;339:27-30.
16. Spivak JL, Pham T, Issacs M, Hankins WD. Erythropoietin is both a mitogen and a survival factor. Blood 1991;77:1228-33.
17. Dessypris EN, Graber SE, Krantz SB, Stone WJ. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 1988; 6:2060-2.
18. Hoffbrand AV, Pettit JE. Color atlas of clinical haematology. London: Mosby-Wolfe, 1994.
19. Chapman RG. Hematologic problems. In: Friedmann HH, ed. Problem-oriented medical diagnosis. Boston/Toronto: Little Brown, 1983:195-234.
20. Pimentel E. Handbook of growth factors: hematopoietic growth factors and cytokines (vol. III). Boca-Raton, FL: CRC Press, 1994:1-19.
21. Damen JD, Krystal G. Early events in erythropoietin-induced signaling. Exp Hematol 1996;24:1455-9.
22. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by interferons α and β. Differing mechanisms despite shared receptors. Exp Haematol 1996;24:204-8.
23. Gullberg U, Bergh G, Ehinger M, Olsson I. Receptors for hematopoietic regulatory cytokines: overview of structure and function. In: Kurzrock R, Talpaz M, eds. Cytokines: interleukin and their receptors. Boston: Kluwer Academic, 1995:1-17.
24. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythoid precursors and its possible role in the pathogenesis of hypoplastic anemia. Br J Hematol 1987;67:11-22.
25. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993;81:2223-6.
26. Erslev A, Soltan A. Pure red cell aplasia: a review. Blood Rev 1996;10:20-8.
27. Erslev AJ, Gabuzda TG. Pathology of blood, 3rd ed. Philadelphia: WB Saunders, 1985.
28. Sawada K, Krantz SB, Kans JS, Dessypris EN, Sawyer S, Glick AD, Civin CI. Purification of human erythroid colony forming units and demonstration of specific binding of erythropoietin. J Clin Invest 1987;80:357.
29. Spivak JL, Douglas KF, Fischer J, Noga SH, Isaacs M, Connor E, Hankins WD. Cell cycle-specific behavior of erythropoietin. Exp Haematol 1996;24:141-50.
30. Kaushansky K, Lin N, Adamson JW. Interleukin-1 stimulated fibroblast to synthesize granulocyte-macrophage and granulocyte colony-stimulating factors: mechanism for the hematopoietic response to inflammation. J Clin Invest 1988;81:92-7.
31. Gelvan D, Fibach E, Meyron-Holtz EG, Konijn AM. Ferritin up-take by human erythroid precursors is a regulated iron pathway. Blood 1996;8:3200-7.
32. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-7.
33. Raja KB, Maxwell PH, Ratcliffe PJ, Salisbury JR, Simpson RJ, Peters TJ. Iron metabolism in transgenic mice with hypoplastic anemia due to incomplete deficiency of erythropoietin. Br J Haematol 1997;96:248-53.
34. Stack HR, Smith T, Jones JH, et al. Measurement of blood and iron loss in colitis with a whole body counter. Gut 1969;10:769-75.
35. Conner NTJ, Hoffbrand AV. Anemia in systemic disease. In: Delamore IW, Lui-Yin JA, eds. Haematological aspects of systemic disease. London: Bailliére Tindall, 1994:33-65.
36. Gasché C, Dejaco C, Waldhoer T, Reinisch W, Tillinger W, Vogelsang H, Gangl A, Lochs H. Double-blind, placebo controlled trial of erythropoietin and iron saccharate for anemia in Crohn's disease [Abstract]. Gastroenterology 1995;108:A821.
37. Geller SA. Pathology of inflammatory bowel disease: a critical appraisal in diagnosis and management. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:336-87.
38. Lichtman SN, Sartor B. Extraintestinal manifestations of inflammatory bowel disease: clinical aspects and natural history. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:327-36.
39. Haurani FI, Burke WM, Martnez EJ. Effective reutilization of iron in the anemia of inflammation. J Cell Physiol 1988;137:188-93.
40. Birgegard G, Hallgren R, Caro J. Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: relationship to anemia and the effect of anti-inflammatory treatment. Br J Haematol 1987;65:479-83.
41. Means RT, Krantz SB. Progress in understanding the pathogenesis of anemia of chronic disease. Blood 1992;80:1639-47.
42. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by human recombinant erythropoietin. Blood 1991;78:2564-7.
43. Vreugdenhil G, Lowenberg B, van Ejik HG, Swaak AJG. Anemia of chronic disease in rheumatoid arthritis: raised serum interleukin (IL-6) levels and the effect of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int 1990;10:127-34.
44. Bernad A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos TC. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity 1994;1:725-32.
45. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-94.
46. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatocoma cultures and in isolated rat perfused kidneys. Life Sci 1991;50:301-8.
47. Ulich TR, del Castillo J, Guo K. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood 1989;73:108-10.
48. Ulich TR, Guo KZ, Remick D, del Castillo J, Yin SM. Endotoxin induced gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J Immunol 1991;146:2316-23.
49. Schreiber S, MacDermott RP, Raedler A, Pinnau R, Bertovich MJ, Nash GH. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991;101:1020-30.
50. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Raedler A. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995; 108:21-33.
51. Schreiber Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995;108:1434-44.
52. Erslev AJ, Caro J, Miller O, Silver R. Plasma erythropoietin in health and disease. Ann Lab Clin Sci 1980;10:250-7.
53. Johannsen H, Jelkmann W, Wiedemann G, Otte M, Wagner T. Erythropoietin/haemoglobin relationship in leukemia and ulcerative colitis. Eur J Hematol 1989;43:201-6.
54. Abel J, Spannbruckner N, Jelkmann Fandrey J, Jelkmann W. Serum erythropoietin levels in patients with sepsis and septic shock. Eur J Haematol 1996;57:359-63.
55. Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Sprengler U. Inadequate erythropoietin response to anemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin 6 and their soluble receptors. Br J Haematol 1997;96:235-9.
56. Eschbach JW, Adamson JW. Guidelines for recombinant human erythropoietin therapy. Am J Kidney Dis 1989;14:2-8S.
57. van der Weyden MB, Cooper M, Firkin BG. Altered erythrocyte pyrimidine activity in vitamin B12 or folate deficiency. Br J Heamatol 1979;42:85-91.
58. Blount BC, Ames BN. DNA damage in folate deficiency. Baillieres Clin Haematol 1995;8:461-78.
59. Cohen SM, Rosenthal DS, Karp PJ. Ulcerative colitis and erythrocyte G6DP deficiency: salicylazosulfapyridine provoked hemolysis. JAMA 1968;205:528-30.
60. van Hees PA, van Elferen LW, van Rossum JM, van Tongeren JH. Hemolysis during salicylazosulfapyridine therapy. Am J Gastroenterol 1978;70:501-5.
61. Doodacre RL, Ali MA, Vanderlinden B, Hamilton JD, Castelli M, Seaton T. Hemolytic anemia in patients receiving sulfasalazine. Digestion 1978;17:503-8.
62. Bernstein CN, Artinian L, Anton PA, Shanhan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994;39:1638-41.
63. Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Dietrich MP, Wachter H. Immune activation and the anemia with associated chronic inflammatory disorders. Eur J Hematol 1991;46:65-70.
64. Kaplinsky N, Frankl O. Salicylazosulphapyridine-induced Heinz body anemia. Acta Haematol 1978;59:310-4.
65. Altman AR, Maltz CR, Janowitz HD. Auto immune hemolytic anemia in ulcerative colitis. Dig Dis Sci 1979;24:282-5.
66. Schreiber S, Raedler A, Stenson WF, MacDermott RP. The immunology of inflammatory bowel disease. Gastroenterol Clin North Am 1992;21:451-502.
67. Sahay R, Orangnell DR, Scott BB. Inflammatory bowel disease and refractory anaemia (myelodysplasia). Gut 1993;34:1630-1.
68. Osborne CK, Sunderland MC, Neidhart JA, Ravdin PM, Abeloff MD. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. Ann Oncol 1994;5:43-7.
69. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33.
70. Best WR, Becktel JM, Singleton JW. Development of a Crohn's disease activity index: National cooperative Crohn's disease study. Gastroenterology 1976;70:439-47.